Hexarelin vs Prostamax
Side-by-side comparison of key properties, dosing, and research.
- Summary
- Hexarelin is a potent synthetic GHRP and the strongest GH secretagogue in its class per unit dose. It also exhibits unique cardioprotective properties through direct binding to cardiac CD36 receptors, independent of GH release. Its potency is balanced by a tendency to desensitize GH release with prolonged use, making cycling important.
- Prostamax is a tetrapeptide bioregulator (Lys-Glu-Asp-Pro) developed by Professor Vladimir Khavinson, tissue-specific for the prostate gland. It supports prostate epithelial cell function, promotes normalization of prostate tissue, and is studied for its potential in benign prostatic hyperplasia (BPH), prostatitis, and prostate anti-aging. It is one of the more widely used Khavinson bioregulators among men over 40.
- Half-Life
- ~70 minutes
- Short (minutes); sustained gene-regulatory effects
- Admin Route
- SubQ
- SubQ, Oral
- Research
- —
- —
- Typical Dose
- 100–200 mcg
- 10 mg per day
- Frequency
- 2–3 times daily
- Daily for 10–30 days
- Key Benefits
- Strongest GH pulse per mcg among GHRPs
- Unique direct cardioprotective effects via CD36
- Increased IGF-1 and muscle anabolism
- Accelerated recovery from training
- Bone density support
- Anti-aging via GH axis
- Potential cardiac rehabilitation benefits
- Supports normalization of prostate tissue architecture
- May reduce prostate enlargement associated with BPH
- Anti-inflammatory effects on prostatic tissue
- Reduces prostate cell apoptosis from oxidative stress
- Potential support in chronic prostatitis
- Anti-aging effects on prostate glandular tissue
- Complementary to conventional BPH therapies
- Side Effects
- Water retention
- Elevated cortisol
- Elevated prolactin (more pronounced than other GHRPs)
- Receptor desensitization with continuous use
- +1 more
- Generally well tolerated in available research
- Mild injection site reactions
- No significant adverse urological events reported at standard doses
- Stacks With
- —
- —